ArticleApplied biochemistry and biotechnology2026
Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate Secondary Brain Injury After Intracerebral Hemorrhage in Rats by Modulating the SIRT6/Notch1/NF-κB Signaling.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the effects and potential mechanisms of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) on secondary brain injury (SBI) after intracerebral hemorrhage (ICH) in rats. BMSC-Exos were isolated and characterized by transmission electron microscopy and Western blot analysis of exosomal markers (CD9, CD63, and TSG101). A rat model of ICH was established by intracerebral injection of Type IV collagenase, and a PC12 cell model of ICH was induced by hemin exposure. Neurological deficits was evaluated using the modified neurological severity score (mNSS). Histopathological changes in the brain of rats were observed by H&E, Nissl, and TUNEL staining. Inflammatory cytokines (TNF-α, IL-1β) and oxidative stress indicators (ROS) were measured by ELISA and fluorescence assays. PC12 cells were co-cultured with BMSC-Exos, and cell viability, apoptosis, and oxidative stress were assessed using CCK-8, LDH release, EdU assay, and flow cytometry. Expression of SIRT6/Notch1/NF-κB pathway proteins were analyzed by Western blot. BMSC-Exos treatment significantly improved neurological function, reducing mNSS scores by approximately 44% at 72 h after ICH (P < 0.001), and decreased brain water content by about 8.7% (P < 0.05). Histopathological analysis showed a 45% reduction in neuronal apoptosis and 41% increase in surviving neurons compared with untreated ICH rats (P < 0.05). Inflammatory cytokines TNF-α and IL-1β were reduced by 33% and 39%, respectively, and ROS production declined by ~ 40% (P < 0.05). In vitro, BMSC-Exos enhanced PC12 cell viability by 49%, reduced LDH release by 30%, and decreased apoptotic cell ratio by 46% following hemin injury (P < 0.05). Mechanistically, BMSC-Exos upregulated SIRT6 expression and suppressed Notch1 and NF-κB p65 phosphorylation, whereas SIRT6 knockdown reversed these protective effects. BMSC-Exos alleviate SBI after ICH by enhancing SIRT6 expression, thereby suppressing Notch1/NF-κB activation and mitigating neuronal apoptosis, oxidative stress, and inflammation.
Indexed as
Identifiers
41870687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.